PuSH - Publication Server of Helmholtz Zentrum München

Li, L.S.* ; Wu, S.* ; Kopp, N.* ; Montero, J.* ; Ryan, J.* ; Chapuy, B.* ; van der Zwet, J.C.* ; Layer, J.* ; Weigert, O. ; Christie, A.L.* ; Christodoulou, A.N.* ; Liu, H.* ; Yoda, A.* ; Hofmann, F.* ; Baffert, F.* ; Vangrevelinghe, E.* ; Gaul, C.* ; Radimerski, T.* ; Letai, A.G.* ; Weinstock, D.M.*

Type II JAK2 inhibitor NVP-CHZ868 is active in vivo against JAK2-dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs).

Blood 124 (2014)
Open Access Green as soon as Postprint is submitted to ZB.
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Meeting abstract
Corresponding Author
ISSN (print) / ISBN 0006-4971
e-ISSN 1528-0020
Journal Blood
Quellenangaben Volume: 124, Issue: 21 Pages: , Article Number: , Supplement: ,
Publisher American Society of Hematology
Publishing Place Washington
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) CCG Pathogenesis of Acute Myeloid Leukemia (KKG-KPL)